Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae

Jacqueline T. Bork; Emily L. Heil; Surbhi Leekha; Randal C. Fowler; Nancy D. Hanson; Anjali Majumdar; J. Kristie Johnson

doi:10.1016/j.diagmicrobio.2017.08.020

Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae

Jacqueline T. Bork, Emily L. Heil, Surbhi Leekha, Randal C. Fowler, Nancy D. Hanson, Anjali Majumdar, J. Kristie Johnson

Department of Medical Microbiology and Immunology

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

Objective: We analyzed the effects of different cefepime MIC breakpoints on Enterobacteriaceae cefepime susceptibility and the presence of AmpC and extended-spectrum β-lactamase (ESBL) genes within the cefepime MIC interpretative categories. Methods: Using Enterobacteriaceae susceptibility data from 2013 comparisons of MIC breakpoints were performed using Pearson's chi-squared test. Molecular testing on a subset of isolates was done. Results: Among 3784 non-duplicate clinical isolates, cefepime susceptibility decreased from 97.6% to 96.1% to 93.7% for CLSI 2013, CLSI 2014, and EUCAST 2011, respectively. In ceftriaxone non-susceptible isolates, cefepime susceptibility decreased from 79% to 66% (P <. 0.0001) using CLSI 2013 and 2014, respectively, which was greater and statistically significant for Escherichia coli and Klebsiella spp. but not for Enterobacter spp. (P = 0.06). Isolates with MIC ≤1. μg/mL more often harbored AmpC (77%) than ESBL (18%) genes. Conclusions: Lower cefepime MIC breakpoints decrease cefepime susceptibility for isolates harboring ESBLs, while sparing the majority of those with AmpCs.

Original language	English (US)
Journal	Diagnostic Microbiology and Infectious Disease
DOIs	https://doi.org/10.1016/j.diagmicrobio.2017.08.020
State	Accepted/In press - 2017

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.diagmicrobio.2017.08.020

Fingerprint Dive into the research topics of 'Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae'. Together they form a unique fingerprint.

Cite this

Bork, J. T., Heil, E. L., Leekha, S., Fowler, R. C., Hanson, N. D., Majumdar, A., & Johnson, J. K. (Accepted/In press). Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease. https://doi.org/10.1016/j.diagmicrobio.2017.08.020

@article{39a8f41fba7845b2af33904266838269,

title = "Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae",

abstract = "Objective: We analyzed the effects of different cefepime MIC breakpoints on Enterobacteriaceae cefepime susceptibility and the presence of AmpC and extended-spectrum β-lactamase (ESBL) genes within the cefepime MIC interpretative categories. Methods: Using Enterobacteriaceae susceptibility data from 2013 comparisons of MIC breakpoints were performed using Pearson's chi-squared test. Molecular testing on a subset of isolates was done. Results: Among 3784 non-duplicate clinical isolates, cefepime susceptibility decreased from 97.6% to 96.1% to 93.7% for CLSI 2013, CLSI 2014, and EUCAST 2011, respectively. In ceftriaxone non-susceptible isolates, cefepime susceptibility decreased from 79% to 66% (P <. 0.0001) using CLSI 2013 and 2014, respectively, which was greater and statistically significant for Escherichia coli and Klebsiella spp. but not for Enterobacter spp. (P = 0.06). Isolates with MIC ≤1. μg/mL more often harbored AmpC (77%) than ESBL (18%) genes. Conclusions: Lower cefepime MIC breakpoints decrease cefepime susceptibility for isolates harboring ESBLs, while sparing the majority of those with AmpCs.",

author = "Bork, {Jacqueline T.} and Heil, {Emily L.} and Surbhi Leekha and Fowler, {Randal C.} and Hanson, {Nancy D.} and Anjali Majumdar and Johnson, {J. Kristie}",

year = "2017",

doi = "10.1016/j.diagmicrobio.2017.08.020",

language = "English (US)",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae

AU - Bork, Jacqueline T.

AU - Heil, Emily L.

AU - Leekha, Surbhi

AU - Fowler, Randal C.

AU - Hanson, Nancy D.

AU - Majumdar, Anjali

AU - Johnson, J. Kristie

PY - 2017

Y1 - 2017

N2 - Objective: We analyzed the effects of different cefepime MIC breakpoints on Enterobacteriaceae cefepime susceptibility and the presence of AmpC and extended-spectrum β-lactamase (ESBL) genes within the cefepime MIC interpretative categories. Methods: Using Enterobacteriaceae susceptibility data from 2013 comparisons of MIC breakpoints were performed using Pearson's chi-squared test. Molecular testing on a subset of isolates was done. Results: Among 3784 non-duplicate clinical isolates, cefepime susceptibility decreased from 97.6% to 96.1% to 93.7% for CLSI 2013, CLSI 2014, and EUCAST 2011, respectively. In ceftriaxone non-susceptible isolates, cefepime susceptibility decreased from 79% to 66% (P <. 0.0001) using CLSI 2013 and 2014, respectively, which was greater and statistically significant for Escherichia coli and Klebsiella spp. but not for Enterobacter spp. (P = 0.06). Isolates with MIC ≤1. μg/mL more often harbored AmpC (77%) than ESBL (18%) genes. Conclusions: Lower cefepime MIC breakpoints decrease cefepime susceptibility for isolates harboring ESBLs, while sparing the majority of those with AmpCs.

AB - Objective: We analyzed the effects of different cefepime MIC breakpoints on Enterobacteriaceae cefepime susceptibility and the presence of AmpC and extended-spectrum β-lactamase (ESBL) genes within the cefepime MIC interpretative categories. Methods: Using Enterobacteriaceae susceptibility data from 2013 comparisons of MIC breakpoints were performed using Pearson's chi-squared test. Molecular testing on a subset of isolates was done. Results: Among 3784 non-duplicate clinical isolates, cefepime susceptibility decreased from 97.6% to 96.1% to 93.7% for CLSI 2013, CLSI 2014, and EUCAST 2011, respectively. In ceftriaxone non-susceptible isolates, cefepime susceptibility decreased from 79% to 66% (P <. 0.0001) using CLSI 2013 and 2014, respectively, which was greater and statistically significant for Escherichia coli and Klebsiella spp. but not for Enterobacter spp. (P = 0.06). Isolates with MIC ≤1. μg/mL more often harbored AmpC (77%) than ESBL (18%) genes. Conclusions: Lower cefepime MIC breakpoints decrease cefepime susceptibility for isolates harboring ESBLs, while sparing the majority of those with AmpCs.

UR - http://www.scopus.com/inward/record.url?scp=85030871877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030871877&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2017.08.020

DO - 10.1016/j.diagmicrobio.2017.08.020

M3 - Article

C2 - 29031525

AN - SCOPUS:85030871877

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

ER -